Vera Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $45,681 | $43,459 |
| Marketable securities | 115,035 | 71,194 |
| Prepaid expenses and other assets, current | 11,307 | 11,045 |
| Total current assets | 172,023 | 125,698 |
| Restricted cash, noncurrent | — | 293 |
| Property and equipment, net | 92 | 51 |
| Operating lease right-of-use assets | 2,949 | 5,173 |
| Prepaid expenses and other assets, noncurrent | 471 | 162 |
| Non-marketable equity securities | 11 | 58 |
| Total assets | $175,546 | $131,435 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $11,118 | $11,991 |
| Operating lease liabilities | 2,436 | 2,645 |
| Accrued expenses and other liabilities, current | 8,749 | 10,964 |
| Total current liabilities | 22,303 | 25,600 |
| Long-term debt | 49,877 | 24,810 |
| Operating lease liabilities, noncurrent | 1,395 | 3,831 |
| Accrued expenses and other liabilities, noncurrent | 286 | 286 |
| Total liabilities | 73,861 | 54,527 |
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 10,000,000 authorized as of December 31, 2023 and December 31, 2022; no shares issued and outstanding as of December 31, 2023 and December 31, 2022 | — | — |
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 44,452,161 and 27,800,861 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 44 | 28 |
| Additional paid-in capital | 410,492 | 290,216 |
| Accumulated other comprehensive gain (loss) | 251 | (224) |
| Accumulated deficit | (309,102) | (213,112) |
| Total stockholders’ equity | 101,685 | 76,908 |
| Total liabilities and stockholders’ equity | $175,546 | $131,435 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.